Pharmaceutical

GUB-014295 by Gubra for Obesity: Likelihood of Approval

GUB-014295 is under clinical development by Gubra and currently in Phase I for Obesity.

Dec 20, 2023 - 18:00
GUB-014295 is under clinical development by Gubra and currently in Phase I for Obesity.
Read the original article

Tags:

Previous Article

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Dis...

Next Article

Meloxicam fast acting by Viatris for Post-Operative Pain: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for...

Apr 19, 2024

Pfizer RSV vaccine seen as effective against severe disease, FDA documents say

Pfizer RSV vaccine seen as effective against severe dis...

May 17, 2023

China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor

China NMPA grants IND clearance for Fermion’s TYK2 JH2 ...

Feb 6, 2024